FDA Clears Tysabri For Limited Clinical Use
Patients who had previously been receiving the multiple sclerosis therapy are now eligible to participate in Biogen Idec/Elan’s pending safety extension study.
Patients who had previously been receiving the multiple sclerosis therapy are now eligible to participate in Biogen Idec/Elan’s pending safety extension study.